



## GUIDELINES and FORMS TABLE OF CONTENTS

<b>1</b>	<b>Guidelines and Forms</b>
1.01	Index to Guidelines and Forms
<b>2</b>	<b>Human Medicines</b>
2.01	General information
2.02	Pharmaceutical and Analytical
2.03	Alcohol content of medicines*
2.04	Post-importation testing*
2.05	Stability *
2.06	Biostudies
2.07	Dissolution*
2.08	Amendments*
2.09	Clinical
2.10	Substitution of medicines
2.11	Adverse Drug Reactions Reporting
2.12	Completing clinical trial applications (to be updated)
2.13	Implementation of the post-registration amendments guideline
2.14	Patient Information Leaflet (PIL)
2.15	Proprietary names for medicines
2.16	Package Inserts for human medicines
2.17	Safety-related Package Insert Notifications (SR-PINs)
2.20	Package Insert standardised texts
2.21	ZA eCTD Module 1 Technical
2.22	eCTD Validation Criteria
2.23	Submission in eCTD format
2.24	Guidance for the Submission of the ZA CTD / eCTD – General & Module 1
2.25	Pharmaceutical & Analytical for CTD
2.26	CTD Implementation Road Map
2.27	eCTD Checksums
2.28	eCTD Questions & Answers
2.30	Biosimilars
2.31	Fixed Dose Combination Products for HIV/Aids, Tuberculosis, and Malaria
2.32	Wound Dressings
2.33	Adverse Drug Reactions reporting post-marketing
2.35	Labelling of medicines containing sugars

2.36 Scheduling of medicines
2.37 Scheduling of substances for prescribing by authorised prescribers
2.38 SI International metric system
2.39 Biological Medicines Pre-registration Consultation Meeting
2.40 Multiple Applications of the same application with different proprietary names
2.41 Emergency Procedures for Clinical Trial Sites
2.42 Post Clinical Trial Drug Access <i>for comment</i>
2.43 Oversight and Monitoring in Clinical Trials
2.44 Cultivation of Cannabis and manufacture for medicinal and research purposes <i>for comment</i>
2.45 Borderline Products <i>for comment</i>
2.46 Co-packaging of medicines – <i>for comment</i>
2.47 Clinical Trial Investigators
2.48 Exemptions – <i>for comment</i>
2.49 Capacity building & transformation in clinical trials research – <i>for comment</i>
2.50 Medicines & Human Reproduction – <i>for comment</i>
2.51 TIE Compensation Model
2.52 Section 21 Access to Unregistered Medicines – <i>for comment</i>
2.53 Investigator workload in clinical trials – <i>for comment</i>
2.54 Quality of medicines used in clinical trials in South Africa – <i>for comment</i>
<b>3 Veterinary Medicines</b>
3.01 General information for Veterinary medicines
3.03 Bioavailability and bioequivalence
3.04 Efficacy of and GCP for veterinary medicines
3.05 Pre-clinical safety for veterinary medicines
3.06 Efficacy of veterinary biological medicines
3.07 Maximum residue limits and withdrawal periods
3.08 Safety of veterinary biological medicines
3.09 Reporting of adverse drug reactions
3.10 Recall of veterinary medicines
3.11 Completing section 21 application form
3.12 Veterinary Orphan Products- <i>for comment</i>
3.13 Veterinary Antimastitis Medicines
<b>4 Good Manufacturing Practice (GMP)*</b>
4.01 SA guide to Good manufacturing Practice (GMP)
4.02 SA Guide to Good Wholesaling Practice + <i>amended for comment</i>
4.03 Aerosol manufacturing
4.04 Isolator technology
4.05 Cephalosporin manufacture
4.06 Penicillin manufacture
4.07 Radiopharmaceutical manufacture
4.08 Site master file
4.08 Inspections involving GMP Inspectors
4.10 Exporting of medicines by Wholesalers
GCP guidelines

<b>5</b>	<b>Miscellaneous</b>
5.01	Importation and exportation of medicines*
5.02	Parallel importation of medicines (PIM) *
5.03	Annual returns: international control*
5.05	Destruction of schedule 5 medicines*
5.06	Destruction of schedule 6 medicines*
5.07	Recalls
5.07	Recall / withdrawal of medicines, medical devices and IVDs - <i>for comment</i>
5.08	Donations*
5.09	Lodging a complaint on a medicine
<b>6</b>	<b>Forms</b>
6.01	MRF1 Medicine Registration Application (Human) - <i>replaced by ZA-CTD</i>
6.02	MRF2 Screening of Application*
6.03	MRF4 Package Insert Amendments*
6.04	ARF1 Adverse Drug Reaction Reporting
6.05	CTF1 Clinical Trial Application
6.06	CTF2 Clinical Trial Protocol Amendments
6.07	CTF3 Clinical Trial Investigators and Sites Amendments
6.08	VMRF1 Veterinary Medicine Registration
6.09	PIF1 Parallel Importation Amendments
6.10	Licence application to manufacture, import or export*
6.11	Licence application to act as wholesaler or distributor**
6.12	Section 21 Application form
6.13	Guideline comments form
6.14	Application for the Donation of Medicine to South Africa
6.15	Screening Template for New Applications for Registration
6.16	Validation Template for eCTD
6.17	Licence application for Wholesaler to export
6.19a	FPP record sheet
6.19b	API record sheet
6.20	Pre-registration Consultation Meeting Check-list
6.21	Licence application to manufacture, import, distribute or export medical devices
6.22	Licence application to import, distribute or export medical devices
6.24	Licence application to wholesale medical devices and IVDs
6.25	Licence application to cultivate, manufacture or import Cannabis for medicinal purposes
6.26	Licence application to wholesale medical devices v2
6.27	CT Six monthly progress report form
6.28	Valproate Annual Risk Acknowledgement Form
	Module 1.2.1 Application Form for ZA-CTD
	ZA-CTD
	ZA util

<b>7</b>	<b>Complementary Medicines (CAMs)</b>
7.01	Complementary Medicines –Quality, Safety, and Efficacy
7.02	Roadmap for Complementary Medicines
7.03	CAMs Use of ZACTD format in preparation of registration application
7.04	Health Supplements – Safety and Efficacy
7.04	Health Supplements – Safety and Efficacy – <i>Annexures for comment</i>
7.05	Complementary Medicines Registration Application ZA-CTD – Quality
7.06	Complementary Medicines – Caffeine and Menthol – <i>for comment</i>
	Government Gazette 38133 Vitamins and Minerals
<b>8</b>	<b>Medical Devices and <i>In Vitro</i> Diagnostics</b>
8.01	General Information – Medical Devices and IVDs – <i>for comment</i>
8.02	Medical Devices and IVDs Essential Principles – <i>for comment</i>
8.03	Medical Devices and IVDs – Conformity Assessment Procedures – <i>for comment</i>
8.04	Adverse event and post-marketing vigilance reporting of medical devices and IVDs – <i>for comment</i>
8.05	Classification of medical devices and IVDs
8.06	Access to and control of medical devices and IVDs – <i>for comment</i>
8.07	Medical Device Quality Manual - <i>for comment</i>
8.08	Medical device IVD technical dossier – <i>for comment</i>
8.09	Medical device non-IVD technical dossier – <i>for comment</i>
	ZA CH1.04: Administrative Information – Application form – Application for registration of a Medical Device – <i>for comment</i>
<b>9</b>	<b>Communication with Industry / All Stakeholders</b>
9.01	Registration of antiretroviral medicines
9.07	ADR terminology used in package inserts
9.08	Dear Healthcare Professional Letter (DHCPL) and Medicines Safety Alerts (MSA)
9.13	Urgent Safety Restriction Notification (USRN)
9.15	Regulation of Complementary Medicines
9.16	Scheduling matters
9.17	Meeting dates 2017
9.22	Scheduling Matters - Accessibility of Malaria Prophylaxis Medicines
9.24	Screening Aug09
9.25	Enoxaparin Dec08
9.28	Cancellation or withdrawal
9.33	Payments made to the Registrar of Medicines
9.38	Implementation of CTD
9.40	Changes during the Registration Process
9.41	Important Medicine safety Information – withdrawal of dextropropoxyphene-containing medicines
9.42	Safety-related Package Insert Notification (SR-PINs) Submission Dates for Pilot Phase
9.46	eCTD Pilot Phase
9.49	Scheduling of Meprobamate - <i>for comment</i>
9.52	Audit of clinical package insert amendments

9.53	Clinical Trial Committee meeting and submission dates
9.55	Scheduling of Codeine
9.56	Correction Notice to GG38133 on vitamins and minerals of Nov 2014
9.57	Process for implementation of amended Regulations 9 and 10 of Nov 2014
9.59	Electronic submission of clinical trial documents
9.61	Scheduling of Aspirin
9.65	Proposal to amend scheduling of codeine and dihydrocodeine - <i>for comment</i>
9.66	Rejections and Comments on rejection
9.68	Scheduling of Ibogaine
9.69	Rescheduling of Diclofenac
9.71	Expression of interest - API full assessment pilot
9.73	Rescheduling of ephedrine, ephedra alkaloids and phenylpropanolamine
9.74	ZA CTD implementation
9.75	Expression of interest - Pilot for electronic submission of ADR reports
9.77	Backlog action plan
9.78	Position statement: Status of Disinfectants, Antiseptics and Germicides
9.79	Medical Device Establishments: Licence requirements
9.80	eCTD Go-live in South Africa
9.81	Workshop re expression of interest on API full assessment pilot
9.82	Rescheduling of acetylcysteine
9.83	Workshop re clinical trial related matters
9.84	Clinical Trial Investigators
9.85	Clarification of process to obtain a licence to grow cannabis for use as a medicine
9.86	2.33 Post-marketing reporting of ADRs to human medicines in South Africa v4.1
9.87	Complementary medicines - Licence application to manufacture and/or wholesale
9.89	MCC wishes to appoint technical evaluators of applications for registration of complementary medicines
9.91	Clinical Trials Workshop
9.92	Rescheduling of albendazole
9.93	Scheduling matters - Regulatory status of cetylpyridinium chloride containing products
9.94	Post-Importation Testing Workshop
9.95	Medical Device Workshop
9.97	Rescheduling of diclofenac
9.96	Transitional arrangements for medical devices
9.98	Meeting between the chief executive officers (CEOs) of pharmaceutical industry, the Chairperson of the Medicines Control Council and the Registrar of Medicines
9.99	Rescheduling of cannabidiol
9.100	Indian Walnut
9.101	Communication with Council or Committees
9.102	MCC wishes to appoint quality and bioequivalence evaluators of applications for registration of medicines
9.103	Tissue Engineering Products
9.104	Rescheduling of Atovaquone & Proguanil
9.105	Section 21 authorisation of sale of unregistered medical devices
9.106	Position statement: Class A Medical Devices
9.107	Medical Device Workshop

9.108 Meeting with CEOs
9.109 Meeting with Medical Device CEOs
9.110 Meeting with Complementary Medicines CEOs
9.111 Rescheduling of Ibuprofen
9.112 Rescheduling of Orphenadrine
9.113 Submission Procedure for Section 21 Re-authorisations
9.114 Submission of Pharmacovigilance Correspondence during protest action
9.115 Submission of Type B Pharmaceutical Amendments during protest action
9.116 Update about ongoing work of SAHPRA during interim closure of Civitas building
9.117 Backlog clearance programme
9.118 Rescheduling of hyoscine butylbromide
9.119 Medical Devices – Extension of Section 36 Exemption Sections 18A and 18B
9.120 Interim Relocation of SAHPRA to CSIR
9.121 Passing away of Lesiba Moshiga
9.122 Status of Cannabis-containing products and the cultivation for medicinal use
Industry Task Group meeting minutes Nov 2014 (revised Dec 2014), March 2015, June 2015, March 2016
<b>10 Media Releases</b>
10.04 Nevirapine 28/07/2003
10.07 Withdrawal of rosiglitazone-containing medicines from the South African (SA) market
10.08 High Court Judgment on Adcock Ingram’s DPP-Containing Medicines
10.09 The Safety of Cough and Cold Medicines in Children
10.10 Registration of Complementary Medicines
10.12 MCC warns against use of the unregistered medicine, Miracle Mineral Solution (MMS) and similar products for the treatment of medical conditions
10.13 MCC alerts the public to the risks and harm associated with the inappropriate and non-prescribed use of testosterone-containing medicines
10.14 MCC clarifies access to Cannabis for the treatment of medical conditions
10.15 Use of Dolutegravir in pregnancy
10.16 Public warned to avoid the purchase of medicines on-line
10.17 Warning on safe use of NSAIDs
10.18 Valsartan
10.19 Press release – On-going work during protest action in Civitas Building, Pretoria
10.20 Press release – New measures to minimise the risk of valproate use in pregnancy
10.21 Press release – Side-effects associated with the use of quinolone and fluoroquinolone antibiotics
10.22 Media Release – Reassurance on the safety of valsartan-containing medicines registered in South Africa
10.23 Media Release – SAHPRA to issue cultivation licences for medicinal cannabis
Withdrawal of VIOXX (rofecoxib) from the South African market
PICs press release Paris 2014
PICs press release Rome 2014
PICs press release Geneva 2015

<b>12</b>	<b>Notification of Registration</b>
12.01 – 12.91	
12.100	Notification of registration until July 2017
12.101	Notification of registration Sept 2017 – June 2018
12.102	Notification of registration July 2018 – March 2019
<b>16</b>	<b>Licensing*</b>
16.01	Licence to manufacture, import or export
16.02	Licence to act as wholesaler or distributor
16.03	Guideline for licence to manufacture, import, export or distribute medical devices and IVDs
16.04	Licence to act as a wholesaler of medical devices & IVDs
<b>17</b>	<b>Fees</b>
17.02	Bank Details
17.03	Retention Fees registration of human and veterinary medicines, and licences
17.04	Fees for Complementary Medicines - <i>for comment</i>
9.33	Payments made to the Registrar of Medicines
	Fees payable Government Gazette 39154 notice 784 01 September 2015
<b>18</b>	<b>Exemptions</b>
18.01	Exemptions in terms of Section 36 of Act 101 – Aug 2005
<b>20</b>	<b>Licences Issued</b>
20.14	Licences issued to manufacturers, importers, exporters, wholesalers, distributors
20.15	Licences issued until September 2017
20.16	Licences suspended March 2015
<b>21</b>	<b>Medicines Safety Alerts (MSA)</b>
21.1	MSA Ketoconazole and Domperidone May06
21.2	MSA Promethazine Apr07
21.3	MSA Rotarix Feb08
21.4	MSA Atypical antipsychotics Jun09
21.5	MSA Gamma benzene hexachloride May09
21.6	MSA Cough and Cold Medicines no longer to be used in Children under the age of two years
	<b>Other documents</b>
	<b>Acts and Regulations</b>
	<b>Policies</b>
	Conflict of interest
	<b>Workshops and Conferences</b>

\* Also applicable to Veterinary medicines